Verona Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Verona Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Verona Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Verona Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Verona Pharma Ltd (Verona Pharma), a subsidiary of Merck & Co Inc, is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is a first-in-class, inhaled dual inhibitor targeting phosphodiesterase 3 and 4 (PDE3 and PDE4). Verona Pharma is focusing on ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also developing a fixed-dose combination of ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (LAMA), for nebulized delivery in COPD treatment. Additionally, the company is evaluating ensifentrine for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis, and asthma. Verona Pharma is headquartered in London, the UK.
Headquarters
United Kingdom
Address
3 More London Riverside, England, SE12RE
Website
www.veronapharma.com
Telephone
44 20 32834200
No of Employees
221
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$42.3M
Verona Pharma Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ensifentrine: Chronic Obstructive Pulmonary Disease (COPD) | Ohtuvayre |
| Pipeline: | |
| Ensifentrine: Non-Cystic Fibrosis Bronchiectasis, Cystic Fibrosis and Asthma |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In October, the company was acquired by Merck for US$10 billion. |
| 2025 | Plans/Strategy | In July, the company announced its plans to be acquired by Merck. |
| 2024 | Regulatory Approval | In June, the company received US Food and Drug Administration (FDA) approval for Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults. |
Competitor Comparison
| Key Parameters | Verona Pharma Ltd | AstraZeneca Plc | Novartis AG | GSK plc | Boehringer Ingelheim International GmbH |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | Switzerland | United Kingdom | Germany |
| City | London | Cambridge | Basel | London | Ingelheim am Rhein |
| State/Province | England | Cambridgeshire | Basel-Stadt | England | Rheinland-Pfalz |
| No. of Employees | 221 | 96,100 | 75,267 | 66,841 | 54,500 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Zaccardelli | Chief Executive Officer; President; Director | Executive Board | 2020 | 59 |
| Mark W. Hahn | Chief Financial Officer | Senior Management | 2020 | 61 |
| Kathleen Rickard, M.D. | Chief Medical Officer | Senior Management | 2019 | 65 |
| Christopher Martin | Chief Commercial Officer | Senior Management | - | - |
| Tara Rheault | Chief Development Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer